Literature DB >> 3349472

Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.

U Harmenberg1, B Wahren, K L Wiechel.   

Abstract

Sera from patients with diseases in the pancreas, gallbladder, and bile duct were analyzed for the tumor markers CA 19-9, CA-50, and carcinoembryonic antigen. In particular CA 19-9 and CA-50 appear to be valuable in differentiating malignant from benign disease in these organs. Our sample of 72 patients with pancreatic cancer also indicates that CA 19-9 and CA-50 complement each other in 21% of the cases. They are also shown to be reliable for monitoring disease: following radical surgery for pancreatic cancer low levels of CA 19-9 and CA-50 were noted, while progressive rises of these tumor markers were related to disease progression.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349472

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Evaluation of CA19-9 serum levels for monitoring disease activity during chemotherapy of pancreatic adenocarcinoma.

Authors:  D J Bac; T C Kok; A van der Gaast; T A Splinter
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  RCAS1, a useful serum marker to predict the recurrence of cancer: two cases of cholangiocarcinoma and pancreatic cancer.

Authors:  Munechika Enjoji; Makoto Nakamuta; Koji Yamaguchi; Kazuhiro Kotoh; Shusuke Morizono; Eiichiro Arimura; Marie Fukushima; Masami Kuniyoshi; Manabu Nakashima; Masao Tanaka; Hajime Nawata
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

Review 3.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.

Authors:  Mark Wahrenbrock; Lubor Borsig; Dzung Le; Nissi Varki; Ajit Varki
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

5.  Tumour markers: An overview.

Authors:  T Malati
Journal:  Indian J Clin Biochem       Date:  2007-09

6.  Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer.

Authors:  C K Ching; J M Rhodes
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

7.  Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.

Authors:  O Nilsson; C Johansson; B Glimelius; B Persson; B Nørgaard-Pedersen; A Andrén-Sandberg; L Lindholm
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

8.  CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.

Authors:  C Haglund; J Lundin; P Kuusela; P J Roberts
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

9.  Carbohydrate Antigen 50: Values for Diagnosis and Prognostic Prediction of Intrahepatic Cholangiocarcinoma.

Authors:  Sukanya Luang; Karuntarat Teeravirote; Waraporn Saentaweesuk; Prasertsri Ma-In; Atit Silsirivanit
Journal:  Medicina (Kaunas)       Date:  2020-11-16       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.